Crinetics Pharmaceuticals (CRNX) Capital Expenditures (2017 - 2026)

Crinetics Pharmaceuticals' Capital Expenditures history runs 10 years deep, the most recent figure standing at $464000.0 for Q1 2026.

• On a quarterly basis, Capital Expenditures rose 75.76% year-over-year to $464000.0 in Q1 2026; TTM through Mar 2026 was $589000.0, a 78.78% decrease from a year earlier, with the FY2025 full-year figure at $389000.0, down 89.88% from the prior year.
• Capital Expenditures advanced to $464000.0 in Q1 2026 per CRNX's latest filing, from $332000.0 in the prior quarter.
• Across five years, Capital Expenditures topped out at $4.2 million in Q2 2025 and bottomed at -$4.4 million in Q3 2025.
• The 5-year median for Capital Expenditures is $264000.0 (2025), against an average of $327588.2.
• Across the five-year window, Capital Expenditures tumbled 7777.78% in 2022 and jumped 8225.0% in 2024, its largest moves.
• Year by year, Capital Expenditures stood at -$1.4 million in 2022, then soared by 132.2% to $445000.0 in 2023, then jumped by 749.89% to $3.8 million in 2024, then plunged by 91.22% to $332000.0 in 2025, then soared by 39.76% to $464000.0 in 2026.
• Per Business Quant, the three latest CRNX Capital Expenditures figures stand at $464000.0 (Q1 2026), $332000.0 (Q4 2025), and -$4.4 million (Q3 2025).